Icon (ICLR) to Release Quarterly Earnings on Wednesday

Icon (NASDAQ:ICLR) is anticipated to announce its Q2 2025 earnings results after the market closes on Wednesday, July 23rd. Analysts expect the company to announce earnings of $3.18 per share and revenue of $1.98 billion for the quarter. Icon has set its FY 2025 guidance at 12.750-14.250 EPS.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, April 30th. The medical research company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.17 by $0.02. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.03 billion. Icon had a return on equity of 11.46% and a net margin of 9.25%. The firm’s revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.47 EPS. On average, analysts expect Icon to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Icon Trading Down 2.6%

NASDAQ ICLR opened at $145.58 on Wednesday. The company has a market cap of $11.76 billion, a PE ratio of 15.86, a PEG ratio of 1.83 and a beta of 1.17. The company has a current ratio of 1.27, a quick ratio of 1.27 and a debt-to-equity ratio of 0.36. Icon has a 12 month low of $125.10 and a 12 month high of $347.72. The stock has a 50 day moving average of $140.58 and a 200-day moving average of $166.76.

Analyst Ratings Changes

Several equities research analysts have recently commented on ICLR shares. JPMorgan Chase & Co. downgraded Icon from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $265.00 to $150.00 in a report on Tuesday, April 29th. Robert W. Baird cut their price objective on Icon from $192.00 to $160.00 and set a “neutral” rating for the company in a report on Friday, May 2nd. Barclays dropped their price target on Icon from $165.00 to $155.00 and set an “equal weight” rating on the stock in a research note on Friday, May 2nd. Evercore ISI increased their price target on Icon from $155.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. Finally, The Goldman Sachs Group dropped their price target on Icon from $180.00 to $160.00 and set a “neutral” rating on the stock in a research note on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $198.08.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.